ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Celon Pharma (CLN.WAR)
Celon Pharma stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Warsaw Stock Exchange · Poland
PLN 18.30▼ -2.66%
Prices as of Oct 27, 2026 · PLN
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Celon Pharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Celon Pharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Celon Pharma a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between PLN 17.24 and PLN 19.45; in 9 out of 10, between PLN 15.49 and PLN 21.65. Estimated annual volatility is 33%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- PLN 1.0B
- Market cap (USD)
- $259M
- P/E ratio
- 9.4
- 52-week high
- PLN 23.50
- 52-week low
- PLN 18.00
- Revenue (12 months)
- PLN 258M
- Gross margin
- 76.7%
- Operating margin
- -17.0%
- Net margin
- 41.5%
- Beta
- 0.62
What this means
ATLAS does not publish a fair value for CLN.WAR right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CLN.WAR has traded between PLN 18.00 and PLN 23.50. Today it is 22.1% below that high and 2% above its low.
On the business: net margin is 41.5%; it trades at 9.4 times earnings.
Its beta is 0.62: it tends to move less than the market.
About the company
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders.
Want to see everything about Celon Pharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Celon Pharma do?
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders.
What is the chance CLN.WAR goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, CLN.WAR ends the month between PLN 17.24 and PLN 19.45.
How big is Celon Pharma and what is its P/E ratio?
Celon Pharma's market capitalization is PLN 1.0B. Its price-to-earnings (P/E) ratio is 9.4: you pay PLN 9.42 for each PLN 1.00 of yearly earnings.
How volatile is CLN.WAR?
ATLAS estimates annual volatility at 33%. In a typical month, half of the outcomes end between PLN 17.24 and PLN 19.45.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer